本帖最后由 老马 于 2013-3-13 13:43 编辑 , Q) C( |# o( W8 O% o+ i9 D' D: x
! A: ~0 `, t8 R. w$ i* d- Y
健择(吉西他滨)+顺铂+阿瓦斯汀5 L. z* u3 [0 u1 c* x
Gemzar +Cisplatin + Avastin
8 M3 n$ l6 W- vhttp://annonc.oxfordjournals.org/content/21/9/1804.full
, `' e _- w" gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + E3 g& w+ M( u) s& o" X: ^# K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. & Z* R0 l) A' x. @( e. G3 v9 c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ X+ T/ G0 g2 [: b. Z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 904)
3 R+ T( ]; f5 A" k( l: T' b S华为网盘附件:# A( U0 {& f/ E* u4 @
【华为网盘】ava.JPG L" _; O! w" c' l
|